United Kingdom - English - HMA (Heads of Medicines Agencies)

ceva santé animale - spiramycin 600000 iu - solution for injection - cattle, pigs - spiramycin

Ireland - English - HPRA (Health Products Regulatory Authority)

ceva animal health limited - erythromycin, cinnamon natural aroma - powder for oral solution - 16.5 %w/w - erythromycin - fowl - chicken - antibacterial

Ireland - English - HPRA (Health Products Regulatory Authority)

ceva santé animale - spine marrow extract - solution for injection - 600 000 iu/ml - spiramycin - bovine - antibacterial

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - telithromycin - tablet, film coated - 400 mg

United Kingdom - English - VMD (Veterinary Medicines Directorate)

ceva animal health ltd - erythromycin - powder for oral solution - antimicrobial - chickens

United Kingdom - English - VMD (Veterinary Medicines Directorate)

ceva animal health ltd - spiramycin - solution for injection - antimicrobial - cattle

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - tulathromycin - antibacterials for systemic use - pigs; cattle; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis sensitive to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment.treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis sensitive to tulathromycin.pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica sensitive to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment. draxxin should only be used if pigs are expected to develop the disease within 2–3 days.sheep: treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent dichelobacter nodosus requiring systemic treatment.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - gamithromycin - antibacterials for systemic use - cattle; pigs; sheep - cattletreatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida and histophilus somni. the presence of the disease in the herd should be established before metaphylactic use.pigstreatment of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis and bordetella bronchiseptica.sheeptreatment of infectious pododermatitis (foot rot) associated with virulent dichelobacter nodosus and fusobacterium necrophorum requiring systemic treatment.

European Union - English - EMA (European Medicines Agency)

aventis pharma s.a. - telithromycin - sinusitis; tonsillitis; bronchitis, chronic; pharyngitis; community-acquired infections; pneumonia, bacterial - antibacterials for systemic use, - when prescribing ketek, consideration should be given to official guidance on the appropriate use ofantibacterial agents and the local prevalence of resistance.ketek is indicated for the treatment of the following infections:in patients of 18 years and oldercommunity-acquired pneumonia, mild or moderate.when treating infections caused by known or suspected beta-lactam- and / or macrolide-resistant strains (according to history of patients or national and / or regional resistance data) covered by the antibacterial spectrum of telithromycin:acute exacerbation of chronic bronchitis;acute sinusitis;in patients of 12 years and oldertonsillitis / pharyngitis caused by streptococcus pyogenes, as an alternative when beta-lactam antibiotics are not appropriate in countries / regions with a significant prevalence of macrolide-resistant s. pyogenes, when mediated by ermtr or mefa.

European Union - English - EMA (European Medicines Agency)

aventis pharma s.a. - telithromycin - community-acquired infections; pharyngitis; bronchitis, chronic; pneumonia; tonsillitis; sinusitis - antibacterials for systemic use, - when prescribing levviax consideration should be given to official guidance on the appropriate use of antibacterial agents and the local prevalence of resistance (see also sections 4.4 and 5.1).levviax is indicated for the treatment of the following infections:in patients of 18 years and older:-community-acquired pneumonia, mild or moderate (see section 4.4).- when treating infections caused by known or suspected beta-lactam and/or macrolide resistant strains (according to history of patients or national and/or regional resistance data) covered by the antibacterial spectrum of telithromycin (see sections 4.4 and 5.1):- acute exacerbation of chronic bronchitis,- acute sinusitisin patients of 12 years and older:- tonsillitis/pharyngitis caused by streptococcus pyogenes, as an alternative when beta lactam antibiotics are not appropriate in countries/regions with a significant prevalence of macrolide resistant s. pyogenes, when mediated by ermtr or mefa (see sections 4.4 and 5.1).